Financials data is unavailable for this security.
View more
Year on year Gilead Sciences Inc had relatively flat revenues (27.28bn to 27.12bn), though the company grew net income 23.34% from 4.59bn to 5.66bn.
Gross margin | 76.04% |
---|---|
Net profit margin | 20.69% |
Operating margin | 28.05% |
Return on assets | 8.96% |
---|---|
Return on equity | 25.70% |
Return on investment | 10.91% |
More ▼
Cash flow in USDView more
In 2023, Gilead Sciences Inc increased its cash reserves by 12.44%, or 673.00m. The company earned 8.01bn from its operations for a Cash Flow Margin of 29.53%. In addition the company used 2.27bn on investing activities and also paid 5.13bn in financing cash flows.
Cash flow per share | 6.60 |
---|---|
Price/Cash flow per share | 10.99 |
Book value per share | 18.33 |
---|---|
Tangible book value per share | -9.58 |
More ▼
Balance sheet in USDView more
Current ratio | 1.43 |
---|---|
Quick ratio | 1.27 |
Total debt/total equity | 1.09 |
---|---|
Total debt/total capital | 0.5234 |
More ▼
Growth rates in USD
SmartText is unavailable
Div yield(5 year avg) | 3.91% |
---|---|
Div growth rate (5 year) | 5.64% |
Payout ratio (TTM) | 67.34% |
EPS growth(5 years) | 1.53 |
---|---|
EPS (TTM) vs TTM 1 year ago | 23.81 |
More ▼